266 related articles for article (PubMed ID: 18607876)
1. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
4. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
8. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
14. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
15. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J
Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820
[TBL] [Abstract][Full Text] [Related]
16. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
17. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
